|
WO2020198051A1
|
|
Inhalable dry powders
|
|
US2019365866A1
|
|
Composition and method for reducing hypoglycemia events in diabetes treatment
|
|
EP3801552A1
|
|
Composition and method for inhalation
|
|
US2019321290A1
|
|
Composition and method for inhalation
|
|
US2019262557A1
|
|
Dry powder drug delivery system
|
|
WO2019210083A1
|
|
Method and composition for treating obesity
|
|
CN112041011A
|
|
Device, system and method for detecting and monitoring inhalation
|
|
AU2019324330A1
|
|
Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
|
|
EP3458133A1
|
|
Apparatus, system and method for detecting and monitoring inhalations
|
|
CN108778249A
|
|
Diskus
|
|
AU2016259332A1
|
|
Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
|
|
AU2016222336A1
|
|
Dry powder drug delivery system and methods
|
|
AU2015275293A1
|
|
A dry powder inhaler and system for drug delivery
|
|
AU2015249177A1
|
|
Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
|
|
US2016095990A1
|
|
Mouthpiece cover for an inhaler
|
|
AU2015224525A1
|
|
Monoclonal antibodies and diagnostic uses thereof
|
|
AU2015203688A1
|
|
Diketopiperazine microparticles with defined specific surface areas
|
|
AU2015203301A1
|
|
Reactor for producing pharmaceutical particles in a precipitation process
|
|
US2015283213A1
|
|
Method for treating hyperglycemia with glp-1
|
|
AU2015202348A1
|
|
An interactive apparatus and method for real-time profiling of inhalation efforts
|
